Barclays PLC Foghorn Therapeutics Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 51,609 shares of FHTX stock, worth $316,363. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,609

Previous 39,920 29.28%

Holding current value

$316,363

Previous $371,000 33.96%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$4.61 - $9.35 $53,886 - $109,292	11,689 Added 29.28%	51,609 $245,000
Q3 2024 Nov 15, 2024	BUY	$4.8 - $9.99 $125,894 - $262,017	26,228 Added 191.56%	39,920 $371,000
Q2 2024 Aug 14, 2024	SELL	$5.05 - $8.0 $28,027 - $44,400	-5,550 Reduced 28.84%	13,692 $79,000
Q1 2024 May 15, 2024	SELL	$2.82 - $7.94 $38,526 - $108,476	-13,662 Reduced 41.52%	19,242 $129,000
Q4 2023 Feb 15, 2024	BUY	$2.94 - $6.76 $86,262 - $198,345	29,341 Added 823.49%	32,904 $212,000
Q3 2023 Nov 07, 2023	SELL	$5.0 - $9.87 $2,540 - $5,013	-508 Reduced 12.48%	3,563 $18,000
Q2 2023 Aug 03, 2023	SELL	$5.37 - $8.84 $32,515 - $53,526	-6,055 Reduced 59.8%	4,071 $29,000
Q1 2023 May 04, 2023	BUY	$4.66 - $8.99 $22,037 - $42,513	4,729 Added 87.62%	10,126 $62,000
Q4 2022 Feb 13, 2023	BUY	$5.44 - $9.46 $24,724 - $42,995	4,545 Added 533.45%	5,397 $34,000
Q3 2022 Nov 03, 2022	SELL	$7.52 - $18.01 $1,173 - $2,809	-156 Reduced 15.48%	852 $7,000
Q2 2022 Aug 12, 2022	SELL	$8.48 - $16.84 $18,401 - $36,542	-2,170 Reduced 68.28%	1,008 $14,000
Q1 2022 May 16, 2022	BUY	$8.87 - $22.1 $28,188 - $70,233	3,178 New	3,178 $48,000

Others Institutions Holding FHTX

# of Institutions

Shares Held

35.7M

Call Options Held

8.7K

Put Options Held

2.4K

View Full List

About Foghorn Therapeutics Inc.

Ticker FHTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,637,400
Market Cap $255M
Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...

More about FHTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account